- Home
- CMPR vs DYN Comparison
CMPR vs DYN Comparison
Compare CMPR & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPR
- DYN
- Stock Information
- Founded
- CMPR 1994
- DYN 1984
- Country
- CMPR Ireland
- DYN United States
- Employees
- CMPR N/A
- DYN N/A
- Industry
- CMPR Publishing
- DYN Medicinal Chemicals and Botanical Products
- Sector
- CMPR Consumer Discretionary
- DYN Health Care
- Exchange
- CMPR Nasdaq
- DYN Nasdaq
- Market Cap
- CMPR 1.2B
- DYN 1.2B
- IPO Year
- CMPR N/A
- DYN 2020
- Fundamental
- Price
- CMPR $48.46
- DYN $9.95
- Analyst Decision
- CMPR Strong Buy
- DYN Strong Buy
- Analyst Count
- CMPR 2
- DYN 15
- Target Price
- CMPR $62.50
- DYN $43.07
- AVG Volume (30 Days)
- CMPR 294.8K
- DYN 3.2M
- Earning Date
- CMPR 07-29-2025
- DYN 08-11-2025
- Dividend Yield
- CMPR N/A
- DYN N/A
- EPS Growth
- CMPR 83.61
- DYN N/A
- EPS
- CMPR 5.97
- DYN N/A
- Revenue
- CMPR $3,366,207,000.00
- DYN N/A
- Revenue This Year
- CMPR $4.65
- DYN N/A
- Revenue Next Year
- CMPR $3.16
- DYN N/A
- P/E Ratio
- CMPR $8.12
- DYN N/A
- Revenue Growth
- CMPR 3.64
- DYN N/A
- 52 Week Low
- CMPR $35.21
- DYN $6.36
- 52 Week High
- CMPR $104.92
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- CMPR 57.88
- DYN 52.19
- Support Level
- CMPR $44.19
- DYN $8.95
- Resistance Level
- CMPR $50.48
- DYN $9.58
- Average True Range (ATR)
- CMPR 2.13
- DYN 0.58
- MACD
- CMPR 0.16
- DYN 0.22
- Stochastic Oscillator
- CMPR 75.95
- DYN 85.89
About CMPR Cimpress plc (Ireland)
Cimpress PLC invests in and builds customer-focused, entrepreneurial, mass-customization businesses for the long term. Mass customization seeks to produce goods and services to meet individual customer needs with near mass production efficiency. Its products and services include a broad range of marketing materials, business cards, signage, promotional products, logo apparel, packaging, books and magazines, wall decor, photo merchandise, invitations and announcements, design and digital marketing services, and other categories. The company's segment includes Vista; PrintBrothers; The Print Group; National Pen and All Other Businesses. It generates maximum revenue from the Vista segment.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.